Topical Composition for Skin Infections Using Keratolytic and Antimicrobial Agents

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for skin infections caused by Human papillomavirus (HPV), such as warts and cancers, have limited cure rates and require cryotherapy, which is not always effective.

Innovation Solution

A pharmaceutical composition comprising at least 18 weight % of a keratolytic agent, including salicylic acid, ethyl pyruvate, and polyvinylpyrrolidone-iodine, applied topically at ambient temperature without cryotherapy, to enhance treatment efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments for skin infections are used, then treatment is provided, but cure rates are limited and cryotherapy is required

Engineering Contradiction:

Improvecure rateVSAvoidtreatment complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent combines multiple active ingredients (keratolytic agent, ethyl pyruvate, polyvinylpyrrolidone-iodine) into a single topical composition to achieve synergistic effects that improve cure rates while eliminating the need for cryotherapy. This merging of multiple therapeutic agents into one formulation directly addresses the contradiction by enhancing reliability without increasing device complexity.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The invention uses a composite pharmaceutical formulation containing keratolytic agents (salicylic acid or calcium thioglycolate), ethyl pyruvate, and polyvinylpyrrolidone-iodine in specific concentrations. This composite material approach creates a multi-functional treatment that achieves higher cure rates for HPV skin infections without requiring additional procedural complexity or cryotherapy equipment.

Inventive Principle:

Principle #40Composite materials

2Reliability

If only keratolytic agents are used, then treatment is simple, but cure rate is lower

Engineering Contradiction:

Improvecure rateVSAvoidnumber of ingredients

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent merges keratolytic agents with ethyl pyruvate and polyvinylpyrrolidone-iodine in a single topical composition, where each component contributes to the overall therapeutic effect. This combination increases the cure rate compared to keratolytic agents alone, while the ingredients are integrated into one formulation rather than requiring separate applications.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The topical composition serves multiple functions simultaneously: the keratolytic agent exfoliates infected skin, ethyl pyruvate provides antiviral and anti-inflammatory effects, and polyvinylpyrrolidone-iodine offers broad-spectrum antimicrobial activity. This multi-functionality in a single product increases cure rates without substantially increasing the number of separate treatment steps.

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Reliability

If cryotherapy is used, then treatment efficacy is improved, but treatment complexity and invasiveness increase

Engineering Contradiction:

Improvetreatment efficacyVSAvoidease of application

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent replaces the mechanical and thermal system of cryotherapy with a chemical pharmacological system. Instead of using extreme cold temperatures to destroy tissue, the invention uses a topical composition with keratolytic agents, ethyl pyruvate, and polyvinylpyrrolidone-iodine that chemically targets and eliminates HPV-infected cells. This substitution maintains treatment efficacy while dramatically improving ease of operation and eliminating the need for specialized cryotherapy equipment and procedures.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition achieves a higher cure rate for skin infections compared to treatments using only keratolytic agents, effectively treating resistant warts and improving outcomes for HPV-related conditions.

Implementation Method 1

a keratolytic agent, wherein the weight % of the keratolytic agent is based on a total weight % of the composition

Methodology Applied

Scientific EffectKeratolysis:

Implementation Method 2

a weight % of polyvinylpyrrolidone-iodine from about 0.1% to about 1%

Methodology Applied

Scientific EffectAntimicrobial action of iodine:

Data Source

PatentUS11833161B2Compositions and methods for treatment of skin infections

Publication Date: 2023.12.05 PEDICIS RESEARCH LLC

AI summary

A pharmaceutical composition for treating skin infections is described herein. A method using a pharmaceutical composition for treating skin infections is described herein. A pharmaceutical composition for treating skin infections may comprise, in 100 parts of the composition, 1-99 parts of a pharmaceutically acceptable excipient; 99-1 parts of a keratolytic; 99-1 parts ethyl pyruvate; and 99-1 parts povidone iodine. A method for treating skin infections may comprise topical application of a composition to an infected skin cell for a treatment period.